Semaglutide Helps 40% of Children Overcome Obesity in Landmark 68-Week Trial
4 Articles
4 Articles
Semaglutide helps 4 in 10 children with obesity lose weight, move below limit in new trial
The STEP Young trial tested once-weekly semaglutide in children aged 6 to 12, alongside a reduced-calorie diet and increased physical activity, and found a greater reduction in BMI than placebo
This content was originally published in Agora RN - Rio Grande do Norte News Portal. Visit https://agorarn.com.br for more Christmas and RN news. In the group that received placebo, with diet and exercise, no children left the classification; the medicine today is only authorized from the age of 12 Read more Rio Grande do Norte news in Agora RN: https://agorarn.com.br ☆ Follow us: Facebook.com/agorarn
Administration of GLP-1 receptor agonists is not approved for these age groups by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA)
Semaglutide Helps 40% of Children Overcome Obesity in Landmark 68-Week Trial
A recent phase 3 clinical trial has revealed that approximately 40 per cent of children with obesity no longer meet the criteria for obesity following 68 weeks of treatment with weekly semaglutide injections. The STEP Young study focused on children aged between six and under twelve years who were diagnosed with obesity. Conducted by Novo […]
Coverage Details
Bias Distribution
- 100% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
